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ABBREVIATIONS 
AAT  Abdominal adipose tissue 
BMI  Body mass index 
BP  Blood pressure 
CI  Confidence interval 
CT  Computed tomography 
DM2  Diabetes mellitus type 2 
ESC  European Society of Cardiology 
ESH  European Society of Hypertension 
GDR  Glucose disposal rate 
HDL  High-density lipoprotein 
HOMA-IR Homeostatic model assessment for insulin resistance 
HR  Heart rate 
HT  Hypertension 
HUNT   Nord-Trøndelag Health Study 
ICC  Intraclass correlation coefficient 
MSNA  Muscle sympathetic nerve activity 
MST  Mental stress test 
PAMELA Pressioni Arteriose Monitorate e Loro Associazioni (Italian BP study) 
SAT  Subcutaneous adipose tissue 
TGs  Triglycerides 
VAT  Visceral adipose tissue 
WHR  Waist-hip-ratio 
WHtR  Waist-height-ratio 
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INTRODUCTION  
During the last decades the incidence and prevalence of cardiovascular disease among 
people in both developed and developing countries have escalated, mainly due to population 
growth and aging [1]. In addition, the prevalence rates of diabetes and obesity are rising steeply, 
leading to a large increase in morbidity and additional deaths if this development continues [2]. 
The negative impact on both the affected individual and on society is considerable. 
Nevertheless, most cardiovascular diseases can be prevented, but early detection is then of 
utmost importance [3]. Expanded knowledge of prediction and detection of cardiovascular risk 
markers is one way to potentially reduce the future disease burden. 
 
Historical context 
During the past 20-30 years, our research group has studied cardiovascular risk markers 
in young men with high and normal screening blood pressure (BP). This selection was made with 
the intent to examine the interaction between the sympathoadrenal system and cardiovascular 
and metabolic risk markers in persons with a wide range of BP levels. The first studies were of 
cross-sectional design. Rostrup et al. showed that high screening BP was associated with 
increased cardiovascular reactivity to mental stress, which again was related to the level of 
plasma adrenaline. Further, they showed that adrenaline was negatively related to lipids in the 
group with the highest screening BP [4]. Moan et al., on the other hand, found that the 
relationship between insulin sensitivity and BP, heart rate (HR) and the levels of the 
catecholamines adrenaline and noradrenaline were independent of the participants’ screening 
BP. Insulin sensitivity also had a stronger negative association with BP and HR during mental 
stress than at rest. Moreover, catecholamine levels during a mental stress test (MST) correlated 
with stress diastolic BP and HR. Only stress diastolic BP and body mass index (BMI) remained 
explanatory variables of insulin sensitivity in a multiple regression analysis [5]. Reims et al. 
found that the catecholamine levels were similar between men with normal versus high 
screening BP, and that the catecholamine levels were related to BP response, especially among 
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men with high screening BP [6]. They also observed a negative association between adrenaline 
release and obesity [7]. 
After some years, several follow-up studies were conducted. In a 20-year follow-up 
study, Strand et al. found that noradrenaline was a positive predictor of future left ventricular 
mass, independent of baseline BP and BMI, in middle-aged men who developed hypertension 
(HT) [8]. Gudmundsdottir et al. using the same material, suggested that screening BP, even 
within the normotensive range, could identify individuals that developed HT [9]. In the men 
who developed HT, baseline adrenaline was found to be an independent predictor of future BP. 
Flaa et al. found that adrenaline and noradrenaline levels during MST were significant 
predictors of future systolic BP [10], but did not influence future homeostatic model 
assessment for insulin resistance (HOMA-IR) [11]. Noradrenaline response to a cold pressor test 
was however found to predict future HOMA-IR [11]. They also discovered that adrenaline 
response during mental stress was a negative predictor of future BMI, waist circumference and 
triceps skinfold [12]. In a paper by Hassellund et al., cardiovascular and sympathoadrenal 
responses to mental stress were found to be relatively stable individual features [13]. In this 
study they also found a tendency of higher mental stress response among the men with the 
highest screening BP.  
In this thesis we had a great opportunity to further explore in which way cardiovascular 
and metabolic risk markers at a young age predict future cardiometabolic risk profile. In Paper I, 
we investigated what could predict masked HT. In Papers II and III, we examined which 
cardiovascular risk markers predicted insulin sensitivity and amount of abdominal adipose 
tissue, respectively. 
 
Masked HT 
The term “masked hypertension” was introduced by Pickering et al. in 2002, though the 
phenomenon had previously been described [14]. The different combinations of office and out-
of-office BP values can yield four BP categories, as shown in Figure 1. Masked HT is defined as 
normal office BP and hypertensive out-of-office BP values [15]. In several studies patients who 
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use BP lowering medication has been included in the group labelled as masked hypertensives. 
However, as argued in the 2013 ESH guidelines, HT is then diagnosed, and not masked [15]. As 
in Paper I, the term will here only be used in regard to untreated individuals. 
 
 
 
 
 
 
 
 
 
Figure 1. Classification of blood pressure status according to office and ambulatory blood 
pressure values. 
 
Prevalence of masked HT is by definition somewhat uncertain, with estimates from 10-
20% in the general population, and even higher in predisposed individuals [16-20]. Masked HT 
is regarded as a cardiovascular risk marker similar to sustained HT [20-23], with comparable 
degree of target organ damage [23-25]. The proportion of affected individuals who develop 
sustained HT is uncertain. In a 5-year follow-up study the authors found 34% persistence of 
masked HT and 31% progression to sustained HT among male white-collar workers [26]. The 
study is limited by the inclusion of the first measurement of BP in their calculations, probably 
leading to a higher office BP than if measured according to guidelines [19]. Further, conducting 
ambulatory BP measurements only during working hours complicates generalisation, especially 
since job strain is associated with masked HT [27]. Moreover, progression according to age-
groups was not accounted for. In a mean 6.6-year follow-up study of pre-hypertensive persons, 
42% of those with masked HT developed sustained HT [28]. And in a 10-year epidemiological 
follow-up study of BP in a randomly selected Italian population (the PAMELA-study), the odds 
ratio of developing sustained HT among men with masked HT was 1.7 with 95% confidence 
interval (CI) 1.3-2.2 [29]. 
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In studies of cross-sectional design, male gender, obesity, diabetes, mental stress, job 
strain, smoking and left ventricular hypertrophy have been associated with masked HT [20, 30-
32]. This is in addition to pre-hypertensive BP values and a hypertensive response to exercise 
[31-33]. Intriguingly, despite the high prevalence and extensive consequences of masked HT, 
long-term predictors of masked HT have to our knowledge not been investigated. 
 
Insulin sensitivity 
Insulin sensitivity describes how sensitive the body is to the effect of insulin. A person 
being insulin sensitive will require smaller amounts of endogenous or exogenous insulin to 
lower the blood glucose level than a person with low insulin sensitivity. Low insulin sensitivity is 
not only essential in the development of diabetes mellitus type 2 (DM2), but it is also, in itself, a 
cardiovascular risk marker [34-36]. Still, far more attention has been paid to predictors of DM2, 
than of insulin resistance (low insulin sensitivity). For instance, how insulin sensitivity predicts 
future insulin sensitivity, i.e. its long-term stability, is not well described. A few studies found 
that markers of glucose metabolism had relatively low long-term stability in children and young 
adults, while insulin sensitivity appeared more stable in middle-aged men [37-40]. Given the 
wide-ranging consequences of reduced insulin sensitivity, other potential predictors are rather 
scarcely described. We know that family history of diabetes yields an increased risk of reduced 
insulin sensitivity [41]. Also family history of HT is associated with lower insulin sensitivity [42, 
43]. In addition, intrauterine influence is thought to play a role, and there is an inverse 
relationship between birth weight and insulin resistance [44, 45]. Elevated sympathetic 
reactivity, measured as noradrenaline response to a cold pressor test, is further found to be a 
positive predictor of future insulin resistance in a similar cohort investigated in our laboratory 
[11]. In addition, plasma noradrenaline levels at rest were found to predict higher plasma 
insulin levels in a study with slightly older participants [46]. In an even older population, both 
metabolic and lifestyle factors were found to predict insulin sensitivity after 20 years of follow-
up [40]. In these 50-year-old men, BMI was the strongest predictor of future insulin sensitivity. 
Family history of diabetes or HT was, however, not accounted for.  
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Prediction of abdominal adipose tissue and family history of diabetes 
Obesity and abdominal adipose tissue (AAT) have for a long time been recognized as 
central elements in the pathogenesis of cardiovascular and metabolic diseases such as reduced 
insulin sensitivity, dyslipidaemia and HT [47-49]. Countless numbers of articles have been 
written about AAT and its impact on cardiovascular and metabolic risk markers and diseases. 
Yet, few have examined possible predictors of AAT in long-term follow-up studies. It has been 
shown that 40-70% of variability of BMI can be attributed to genetic factors [50]. BMI has a high 
degree of long-term stability, which makes it a predictor of obesity in later life [51]. However, 
adipose tissue distribution and dysfunction may increase the cardiovascular risk more than 
obesity per se [52]. An interesting study compared persons with either family history of obesity 
or family history of diabetes, and found that adipose tissue dysfunction was only associated 
with the latter [53]. Ensuing studies have also found that family history of diabetes is associated 
with adipose tissue dysfunction, and increased amount of AAT [45, 54]. Family history of HT has 
also been linked to overweight [55-57]. In follow-up studies of non-diabetic Japanese 
Americans, insulin level, C-peptide and circulating leptin level all predicted increased abdominal 
visceral adipose tissue (VAT) after 5 and 10 years [58]. Further, our research group has 
previously established a negative association between adrenaline response to mental stress test 
and future body fat [12]. While noradrenaline, on the other hand, was found to be a positive 
predictor of future weight gain [59]. 
Traditionally, the AAT has been divided into subcutaneous adipose tissue (SAT) and VAT. 
The recognition of two distinct different layers of SAT, namely the superficial and the deep SAT, 
were essentially first appreciated in the late 1990s and early 2000s [60-62]. Still, surprisingly few 
studies have investigated these metabolically different layers separately. As follows, there have 
been diverging results regarding the association between SAT and cardiovascular and metabolic 
risk markers [63]. Deep SAT has been associated with insulin resistance and higher 
cardiovascular risk independent of other adiposity measures [61, 62, 64]. No study has 
investigated the impact of family history of diabetes on the two SAT sub-compartments. 
Moreover, predictors of AAT in men with family history of diabetes are also unknown. 
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AIMS OF THE THESIS 
In this thesis, a mean 17.3 years follow-up study of a homogenous group of healthy young men 
was performed. The aims were: 
 
x To test if high blood pressure at the military screening or at baseline examinations could 
predict future blood pressure, measured as both office and ambulatory blood pressure.  
We also wanted to investigate whether level of catecholamines during rest or a mental 
stress test was related to future blood pressure (Paper I) 
 
x To test if common cardiovascular risk markers, including baseline insulin sensitivity, body 
mass index and family history of diabetes or hypertension predicted future insulin 
sensitivity, when measured by the “gold standard” method (hyperinsulinaemic 
isoglycaemic glucose clamp) both at baseline and at follow-up (Paper II) 
 
x To test if baseline insulin sensitivity, body mass index, adrenaline response to a mental 
stress test, and family history of diabetes or hypertension predicted future amount of 
the abdominal adipose tissue layers assessed by computed tomography (Paper III) 
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MATERIAL AND METHODS 
Participants 
A flow diagram of the examinations is presented in Figure 2. All participants were young 
men initially recruited from the yearly military draft procedures in Oslo and Akershus, Norway, 
in the period 1988-1996. The participants were selected from different BP percentiles to ensure 
a good BP-range in the ensuing studies of the relation between BP and other cardiovascular risk 
markers. Two to six years after the military draft, five independent studies were conducted by 
four medical doctors during the years 1991-2002. These five studies were gathered, and 
constitute the baseline examination in the present study. Of the 103 men re-examined at 
follow-up (2012-2013), 73 had high screening-BW;шϭϰϬͬϵϬŵŵ,ŐͿĂƚƚŚĞŵŝůŝƚĂƌǇĚƌĂĨƚ͘ 
 
  
 
 
 
All participants were Caucasian men, mean age of 22.0 (± 0.9) years at baseline, and 
none used any medication. In our follow-up study, we wanted to investigate the influence from 
early cardiovascular risk markers, including clamp-derived insulin sensitivity, on the future 
cardiovascular risk profile. An absolute inclusion criterion was therefore having conducted a 
satisfactory hyperinsulinaemic isoglycaemic glucose clamp at baseline, which was achieved in 
158 men. From January 2012 to November 2013, 17.3 (12.3-21.3) years after baseline 
examinations, we re-examined 103 of these 158 men. We were unable to get in contact with 29 
Figure 2. Flow diagram. Baseline examinations (1991-2002) were conducted 2-6 years after 
military draft screening. Follow-up examinations were performed in 2012 and 2013. 
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men and 19 did not respond or responded negatively to the invitation. Of the 110 men initially 
wanting to participate, seven were unable to attend due to mental health problems (n=2), 
practical challenges (n=3), a change of mind (n=1), and one died in a traffic accident. In Paper I 
three participants did not want to undergo ambulatory BP measurements, leaving 100 men 
included in the study. In Paper II the clamp was technically unsuccessful in three participants, 
leaving 100 men in that study as well. In Paper III, we were not able to attain computed 
tomography (CT) in eight men and one was excluded due to a 36 % weight loss since baseline, 
ůĞĂǀŝŶŐϵϰƉĂƌƚŝĐŝƉĂŶƚƐ͘ 
Of the 103 men examined at follow-up, 13 used one or more of the following drugs: 
thyroid hormone replacement drug (n=1), antidepressants (n=3), oral anti-diabetic drug (n=1), 
antipsychotics (n=1), BP lowering medication (n=7) and cholesterol lowering medication (n=3).  
 
Methods 
Baseline examinations 
Differences and similarities between baseline examinations are outlined in Table 1. A 
hyperinsulinaemic isoglycaemic glucose clamp was conducted on all participants at baseline. As 
outlined in Table 1, 39 participants were clamped for only 90 minutes, the rest for 120 minutes. 
During four of the examinations, sitting office BP was measured. In a fifth, only supine 
measurements were done after vein puncture and with a heating sleeve attached [65]. Due to 
potential stress induced by having a venflon and a heating sleeve, and different BP due to 
posture [66]͕ ŽĨĨŝĐĞ W ĨƌŽŵ ƚŚŝƐ ƐƚƵĚǇ ǁĂƐ ŶŽƚ ƵƐĞĚ͘ /Ŷ ƚŚĞ ƐƚƵĚŝĞƐ ďǇ ƌ ,ƆŝĞŐŐĞŶ ĂŶĚ ƌ
Fossum, ambulatory daytime BP was undertaken in most of the participants, resulting in 28 
valid measurements. In one study, adrenaline was infused after 90 minutes of clamp [67], and 
catecholamine values from subsequent MST were therefore not included in the analyses. 
Otherwise, MST was conducted in all studies, with the catecholamines noradrenaline and 
adrenaline measured during rest (mean of four samples during clamp) and MST (mean of four 
samples). This yielded catecholamine-values in 86 participants, all measured by a 
radioenzymatic technique. Due to multicollinearity between adrenaline at rest and during MST, 
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we only used the latter, being the most clinically relevant in previous studies [12, 68]. In one of 
the studies a heating sleeve for “arterialization” of venous blood was not used during clamp 
[69]. Due to the use of incomparable methods of insulin analyses in the baseline studies, insulin 
measurements are not included. As follows, we could not calculate the ,KD-IR. 
 
Table 1. Differences and similarities in baseline studies 
 
     Moan  ,ƆŝĞŐŐĞŶ;ĂͿ ,ƆŝĞŐŐĞŶ;ďͿ Fossum Reims 
Military draft, year 1988 1991 and 1993 1993 1993 1996 
Birth, year 1969-1971 1971-72 1972-75 ϭϵϳϰ-75 1977-78 
Baseline, year 1991-1993 ϭϵϵϰĂŶĚϭϵϵϲ 1995-96 1995-96 2000-02 
Clamped at baseline, n* 50 18 20 28 51 
Study participants, n    39 11 13 ϭϰ 26 
Clamp duration, min   120 120 90 120 90 
,ĞĂƚŝŶŐƐůĞĞǀĞ ͕ǇĞƐͬŶŽ   Yes Yes Yes Yes No 
Screening BP 98
th, 50th and 
2nd percentile 
шϭϰϬͬϵϬmm,Ő шϭϰϬͬϵϬmm,Ő шϭϰϬͬϵϬŵŵ,Ő ш ϭϰϬͬϵϬ and 
чϭϭϱͬϳϱŵŵ,Ő 
a = study without adrenaline infusion, b= study with adrenaline infusion 
*Some participants were included in more than one study 
 
Follow-up examinations 
Hyperinsulinaemic isoglycaemic glucose clamp 
Insulin sensitivity was assessed with a 120 minutes hyperinsulinaemic isoglycaemic 
glucose clamp, using a modification of the method first described by DeFronzo et al. [70] and 
later validated [71, 72] (Figure 3). We did not use a heating sleeve, and in contrast to our 
ƉƌĞǀŝŽƵƐĞǆĂŵŝŶĂƚŝŽŶƐ͕ǁĞƵƐĞĚ ƚŚĞŚƵŵĂŶ ŝŶƐƵůŝŶ ĂŶĂůŽŐƵĞ,ƵŵĂůŽŐ ;/ŶƐƵůŝŶ >ŝƐƉƌŽ͕ůŝ >ŝůůǇ͕
,ŽƵƚĞŶ͕dŚĞNetherlands) instead of Actrapid (Novo Nordisk, Bagsvaerd, Denmark), which was 
ƵƐĞĚĂƚďĂƐĞůŝŶĞ͘ĨƚĞƌŝŶƚƌĂǀĞŶŽƵƐĐĂƚŚĞƚĞƌŝǌĂƚŝŽŶ;sĞŶĨůŽWƌŽϭϴ'͕,ĞůƐŝŶŐďŽƌŐ͕^ǁĞĚĞŶͿ
into the left antecubital vein, baseline blood samples were drawn. The venflon was kept patent 
using physiological saline. The average of 3 blood glucose values (Accu-Chek Performa meter 
system, Roche, Mannheim, Germany) was used as clamping value. Right antecubital vein, to be 
used for insulin and glucose infusions, was subsequently catheterised (BD Venflon Pro 18GA, 
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,ĞůƐŝŶŐďŽƌŐ͕^ǁĞĚĞŶͿ͘dŽƉƌĞǀĞŶƚŝŶƐƵůŝŶĨƌŽŵĂĚŚĞƌŝŶŐƚŽƚŚĞƚŚŝŶĞǆƚĞŶƐŝŽŶůŝŶĞ;KE^d
ŐƌĞĞŶ ůŝŶĞ Ϭϳ-W͕ >ĞŶƐĂŚŶ͕'ĞƌŵĂŶǇͿ͕ ϰ ŽĨ ƚŚĞϭϬϬŵ>EĂů ;ϵŵŐͬŵ>͕ ͘ ƌĂƵŶ͕DĞůƐƵŶŐĞŶ͕
'ĞƌŵĂŶǇͿǁĞƌĞƌĞƉůĂĐĞĚǁŝƚŚϰŵ>ŽĨƚŚĞƉĞƌƐŽŶ͛ƐďůŽŽĚ͕ĂŶĚƚŚĞŶŐĞŶƚůǇŵŝǆĞĚǁŝƚŚϯϬ/ŽĨ
the human insulin analogue. This was infused (Pilot Delta, Fresenius Vial, Brézins, France) at a 
ĐŽŶƐƚĂŶƚƌĂƚĞŽĨϭŵhͬŵŝŶͬkg body weight. Using an Optima MS Fresenius pump (Vial, Brézins, 
France), glucose ;ϮϬϬŵŐͬŵ>͕B. Braun, Melsungen, Germany) infusion was started 5 minutes 
ĂĨƚĞƌƚŚĞŝŶĨƵƐŝŽŶŽĨ ŝŶƐƵůŝŶǁĂƐƐƚĂƌƚĞĚ͕ ŝŶŝƚŝĂůůǇĂƚϮϬŵ>ͬŚĨŽƌϱŵŝŶƵƚĞƐ͕ƚŚĞŶϯϬŵ>ͬŚĨŽƌϱ
minutes, and subsequently adjusted according to glucose values measured in the opposite arm 
every 5 minutes. Glucose disposal rate (GDR) was calculated as the average glucose infusion 
ƌĂƚĞĨƌŽŵƚŚĞůĂƐƚϮϬŵŝŶƵƚĞƐĚŝǀŝĚĞĚďǇďŽĚǇǁĞŝŐŚƚ;ŵŐͬŵŝŶͬŬŐͿ͕ŚĞŶĐĞƚŚĞŚŝŐŚĞƌ'Z͕ƚŚĞ
better insulin sensitivity. This technique has shown acceptable short-time reproducibility [71-
73]. 
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Figure 3. Hyperinsulinaemic isoglycaemic glucose clamp. A constant insulin infusion is initiated. 
After 5 minutes, the glucose infusion starts (grey line), and we attempt to keep the participants’ 
blood glucose (black line) at their fasting level by adjusting the glucose infusion rate depending 
on blood glucose values measured every 5 minutes. Based on the glucose infusion rate the last 
20 minutes, divided by body weight, glucose disposal rate is calculated. Adapted from Moan A 
et al. Metabolism 1994; 43: 423-27. Created by Reims, HM. 
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Office blood pressure measurements 
All office BP measurements were conducted within the first half hour after the 
participant’s arrival. The participants were thoroughly informed of the ensuing BP 
measurements, and the examinations to come. The circumferences around both mid-upper 
arms were measured, and the correct cuff-size chosen. If discordance as to which cuff to be 
used, we used the circumference of their non-dominant arm, since that arm was going to be 
used for ambulatory BP measurements. After attaching the cuff the participants were instructed 
to sit comfortably, in silence, without their legs crossed, for 5 minutes, while both the doctor 
and the assistant were in the room preparing for the ensuing examinations. The assistant 
measured the BP at least three times, at 30 seconds time intervals. If the first two readings 
differed by more than 5 mmHg in systolic value, additional measurements were done (mean 
number of measurements was 3.5). Subsequently the same procedure was done on the other 
arm, also with 5 minutes of rest after attaching the cuff. Mean BP was calculated after excluding 
the first measurement. Oscillometric BP was measured with Dinamap CARESCAPE V100 with 
standard cuff (DURA-CUF 23-33 cm), large cuff (DURA-CUF 31-40 cm) or small cuff (DURA-CUF 
17-25 cm). Subsequently, the assistant left the room. The doctor, unaware of the first BP values, 
then measured BP in both arms with a mercury sphygmomanometer, following the same 
protocol. HR and BP measured at 0, 60, 90 and 120 minutes of clamping were also measured 
with Dinamap CARESCAPE V100. Only HR values were used from these measurements. BP 
values categorizing participants as hypertensives were according to ESH/ESC guidelines; systolic 
ŽĨĨŝĐĞWшϭϰϬŵŵ,ŐĂŶĚͬŽƌĚŝĂƐƚŽůŝĐшϵϬŵŵ,Ő[74]. 
 
Ambulatory blood pressure measurements 
Ambulatory BP was measured in the non-dominant arm, or in the arm with persistent BP 
ш ϭϬŵŵ,Ő ŚŝŐŚĞƌ ƚŚĂŶ ŝŶ ƚŚĞ ŽƚŚĞƌ Ăƌŵ ;ŶсϭͿ͘ KƌĂů ĂŶĚǁƌŝƚƚĞŶ ŝŶƐƚƌƵĐƚŝŽŶs were given. A 
calibrated and validated BP measuring device (Microlife WatchBP O3, Microlife Health 
Management Ltd, Cambridge, United Kingdom) was used [75]. Time of application was around 
14.30 on the examination day for most of the participants. They were instructed to keep their 
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arm still during measurements, and asked to report unexpected events or markedly 
deterioration of sleep. During daytime (06.00-22.00) BP was recorded at 20 minutes intervals 
and during night (22.00-06.00) at 30 minutes intervals. The recordings took place on a working 
day, and they were encouraged to maintain normal daily activities, except physical training. 
Time of awakening and sleeping was assessed in 90% of participants. To avoid any potential 
confounding from awareness of high BP [76], they were not informed of their office BP until 
they had completed a successful ambulatory BP measurement. Ambulatory BP values 
categorising subjects as hypertensives were according to 2007 ESH/ESC guidelines; daytime 
ƐǇƐƚŽůŝĐWшϭϯϱŵŵ,ŐĂŶĚͬŽƌĚŝĂƐƚŽůŝĐWшϴϱŵŵ,Ő͕ŽƌŶŝŐŚƚ-ƚŝŵĞ ƐǇƐƚŽůŝĐWшϭϮϬŵŵ,Ő
ĂŶĚͬŽƌĚŝĂƐƚŽůŝĐWшϳϬŵŵ,Ő[74]. Men with office BP of at least 140/90 mmHg, but normal 
out-of-office BP values, would be labelled as white-coat hypertensives [19]. Men with normal 
office BP and hypertensive ambulatory BP values were identified as masked hypertensives. If 
they had hypertensive values in both office and ambulatory BP measurements, they were 
classified as having sustained HT. All ambulatory BP measurements met the ESH/ESC guidelines 
recommendations at that time of at least 14 measurements during day, and seven at night [77].  
 
Computed tomography 
CT was performed on a different day than the whole-day examination. To assess any 
significant weight change, the participants were weighed in the same way as on the whole-day 
examination. Intraclass correlation coefficient (ICC) value between the two weight 
ŵĞĂƐƵƌĞŵĞŶƚƐǁĂƐϬ͘ϵϴǁŝƚŚϵϱй/ŽĨϬ͘ϵ7-0.99. CT was performed using a Siemens Somatom 
Sensation 64 CT Scanner (Erlangen, Germany) with the participant examined in a supine 
position, arms extended above the head. One single axial scan was performed without 
intravenous contrast medium, through the mid-abdomen, at the level of L3/4. CT parameters 
were 120 kV, 200 mAs, and slice thickness 5 mm. The dicom images were analysed using Osirix v 
ϱ͘ϴ͘Ϯ͕ϯϮďŝƚ(Pixmeo, Geneva, Switzerland). The circumferences were tracked for the superficial 
and deep SAT compartments, divided by a membranous fascia, and for the muscle 
compartment including the spine (Figure 4). The VAT compartment was measured by tracking 
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the inner abdominal circumference, and calculated by highlighting the pixels containing fat (-30 
to -190 Hounsfield Units). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Axial CT scan at level L3/4 showing VAT (visceral adipose tissue), dSAT (deep 
subcutaneous adipose tissue) and sSAT (superficial subcutaneous adipose tissue). 
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Questionnaire 
A validated food questionnaire (SmartDiet) [78, 79] was used to assess dietary habits. It 
also included a question of frequency of 30 minutes physical activity per week. An extensive 
questionnaire regarding education, activity and stress related to profession, leisure activity, 
screen time, family history of disease, own health and use of medication, as well as tobacco and 
alcohol-habits was answered at the end of the day (Appendix, in Norwegian). For validation, 36 
participants answered the two questionnaires again after two weeks. 
 
Anthropometric measurements 
Waist circumference was measured directly on the skin, midway between the inferior 
margin of the last rib and the crest of the ileum in the mid-axillary line, with relaxed posture 
and at the end of normal expiration. Hip circumference was recorded over underwear, at the 
level of maximum posterior extension of the buttocks. Measurements were recorded to the 
nearest 0.1 cm and repeated by the assistant (unaware of the first values). If the two 
measurements disagreed by more than 1 cm, a third measurement was taken. The average 
values from the (last) two measurements were used. 
Height was measured using a KaWe person-check height-measuring device. The 
participants were measured without shoes, standing right with heels against the wall with the 
head in Frankfurt horizontal plane. The measurement was performed twice, and with 
disagreement of more than 0.5 cm, a third time. Recordings were done to the nearest 0.1 cm, 
and the average values from the (last) two measurements were used. 
Weight was measured to the nearest 0.1 kg using a digital scale (OBH Nordica, digital, 
150 kg), wearing light indoor clothing, excluding shoes, belt and sweater, and with empty 
pockets. One kg was subtracted to compensate for clothing.  
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Statistics  
The data were analysed using the statistical software package SPSS for Windows version 
20-22 (IBM SPSS, Chicago, IL, USA). Parametric tests were applied for normally distributed data, 
and non-parametric test for non-normally distributed data. To investigate changes in 
continuous variables between baseline and follow-up, paired sample t-test or Wilcoxon signed-
rank test were used. Independent sample t-test or Mann-Whitney U test were used to compare 
differences in continuous variables between two groups. One-way analysis of variance (ANOVA) 
or Kruskal-Wallis test were performed to compare continuous variables between 
normotensives, masked hypertensives and sustained hypertensives at follow-up in Paper I. 
Further, multiple comparisons were performed using Tukey’s test. The chi square test or 
Fisher’s exact test for contingency tables were applied to detect associations between 
categorical independent variables. In Paper I, a multivariable analysis using the logistic 
regression model was performed to identify independent risk markers of masked HT, using a 
manual backward elimination procedure. Any variable with p < 0.25 from the univariable 
logistic regression analysis was considered a candidate for the multivariable model. Two-tailed 
p-values below 0.05 led to rejection of the null hypothesis.  
In Papers II and III, Pearson (rp) or Spearman (rs) correlations were applied. Subsequent 
multiple linear regression analyses with a manual backward elimination procedure was 
performed including variables correlating with the outcome with p-value < 0.25 from 
univariable analysis, or being clinically relevant. Variables with more than 15% of the data 
missing were not considered. The degree of tracking in Paper II was assessed by Spearman’s 
rank or Pearson’s correlation coefficient between baseline and follow-up measurements [80]. 
ICC was used to assess concordance between Humalog and Actrapid insulin in Paper II, 
and between weight at the whole-day examination and at the CT-scan in Paper III. 
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SUMMARY OF PAPERS 
 
Paper I: High screening blood pressure at young age predicts future masked hypertension: A 
17 year follow-up study 
In this long-term follow-up study, we investigated cardiovascular risk markers in 100 
healthy young men with high or normal screening BP from the military draft. At follow-up, men 
with high screening BP had 4.8 times higher likelihood of masked HT, than men with normal 
screening BP. In addition, only 25% of the 40 men with masked HT had high normal office BP at 
follow-up, and would thus be recommended ambulatory BP measurement according to 
guidelines. The remaining 75% would thus, by following the current guidelines, be wrongly 
labelled as normotensives. Another interesting result was that we observed a reduction in office 
BP from baseline to follow-up. This finding brings attention to the importance of accuracy in BP 
measurement. 
 
Paper II: Family history of hypertension and serum triglycerides predict future insulin 
sensitivity: a 17-year follow-up study of young men 
Cardiovascular risk markers, including insulin sensitivity measured by the gold standard 
method, hyperinsulinaemic isoglycaemic glucose clamp, were examined in 100 men at baseline 
and at follow-up after mean 17 years. We found that having a first-degree relative with HT and 
baseline triglycerides were negative predictors of future insulin sensitivity, an effect largely 
confined to men with a family history of diabetes. Moreover, in contrast to the majority of 
cardiovascular risk markers, insulin sensitivity measured by glucose clamp was not a long-term 
stabile feature. Our results indicate that special attention should be paid to individuals with a 
family history of diabetes or hypertension, despite potentially normal insulin sensitivity at young 
age. 
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Paper III: Predictors of abdominal adipose tissue compartments: 18-year follow-up of young 
men with and without family history of diabetes 
This was a mean 18-year follow-up study of 94 men, having measured cardiovascular risk 
markers at baseline and AAT by CT at follow-up. In multiple regression analyses, baseline BMI 
and family history of diabetes remained positive predictors of future abdominal superficial and 
deep SAT, and VAT, while high-density lipoprotein (HDL) cholesterol remained a negative 
predictor. Baseline risk markers were more strongly associated with future AAT in men with 
versus without family history of diabetes. In men without a family history of diabetes the 
amount of AAT seemed predominantly dependent on their current metabolic profile. In 
addition, family history of diabetes was more positively related to amount of VAT and deep SAT, 
than to amount of superficial SAT. The increased risk of unfavourable metabolic features 
associated with family history of diabetes could thus potentially be caused by an impaired 
ability to store excess fat as superficial SAT. 
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DISCUSSION 
Methodological aspects 
All participants were recruited from the military draft procedures in Oslo and Akershus, 
Norway, and 71% of the men examined at follow-up had high screening BP (шϭϰϬͬϵϬŵŵ,ŐͿ. In 
ϭϵϵϲ͕ůĞƐƐƚŚĂŶϲй;ϮϬϯŽĨϯϰϭϱͿŽĨŵĞŶĂƚƚŚĞŵŝůŝƚĂƌǇĚƌĂĨƚŚĂĚŚŝŐŚƐĐƌĞĞŶŝŶŐW͘KƵƌŵĂŝŶ
finding in Paper I͕ƚŚĂƚŚŝŐŚƐĐƌĞĞŶŝŶŐWƉƌĞĚŝĐƚĞĚĨƵƚƵƌĞŵĂƐŬĞĚ,d͕ǁĂƐĂĚŝƌĞĐƚƌĞƐƵůƚŽĨƚŚŝƐ
selection. We evaluated whether the results in Papers II and III also could have been influenced 
ďǇƐĞůĞĐƚŝŽŶ͘dŚĞƌĞǁĞƌĞŶŽƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞƐŝŶŝŶƐƵůŝŶƐĞŶƐŝƚŝǀŝƚǇďĞƚǁĞĞŶƚŚĞŐƌŽƵƉƐǁŝƚŚ
ŚŝŐŚ Žƌ ŶŽƌŵĂů ƐĐƌĞĞŶŝŶŐ W͘ dŚŝƐ ŝƐ ŝŶ ůŝŶĞ ǁŝƚŚ ƚŚĞ ŵŝƐƐŝŶŐ ĂƐƐŽĐŝĂƚŝŽŶ ďĞƚǁĞĞŶ ŝŶƐƵůŝŶ
sensitivity and screening BP found by Moan et al. ΀ϱ΁͘dŚĞƌĞǁĂƐ͕ŚŽǁĞǀĞƌ͕ĂƚĞŶĚĞŶĐǇŽĨůŽǁĞƌ
ŝŶƐƵůŝŶƐĞŶƐŝƚŝǀŝƚǇĂŵŽŶŐŵĞŶǁŝƚŚŚŝŐŚƐĐƌĞĞŶŝŶŐW;ƵŶƉƵďůŝƐŚĞĚĚĂƚĂͿ͘>ŝŬĞǁŝƐĞ͕ĂŵŽƵŶƚŽĨ
dǁĂƐŶŽƚƐŝŐŶŝĨŝĐĂŶƚůǇĚŝĨĨĞƌĞŶƚďĞƚǁĞĞŶƚŚĞƚǁŽŐƌŽƵƉƐ͕ďƵƚƚŚĞĂŵŽƵŶƚŽĨĂůůƚŚƌĞĞĂĚŝƉŽƐĞ
tissue layers was largĞƌ ĂŵŽŶŐ ŵĞŶ ǁŝƚŚ ŚŝŐŚ ƐĐƌĞĞŶŝŶŐ W ;ƵŶƉƵďůŝƐŚĞĚ ĚĂƚĂͿ͘ dŚĞǇ ǁĞƌĞ
analysed together, but we can thus not exclude that a higher number of participants could have 
ůĞĚƚŽĂƐŝŐŶŝĨŝĐĂŶƚĚŝĨĨĞƌĞŶĐĞŝŶŝŶƐƵůŝŶƐĞŶƐŝƚŝǀŝƚǇĂŶĚĂŵŽƵŶƚŽĨdĂccording to screening BP 
group. All were young Caucasian men, further limiting the generalizability. On the other hand, 
by examining such a homogenous group, we reduced statistical variance. 
  DĞĂƐƵƌŝŶŐ W Ăƚ ƚŚĞ ŵŝůŝƚĂƌǇ ĚƌĂĨƚ ũƵƐƚ ŽŶĐĞ ;ŶŽƚ ƚŚƌĞĞ ƚŝŵĞƐͿ is not according to 
guidelines, and one can assume that for many of the young men, this situation was conceived as 
ƐƚƌĞƐƐĨƵů͘dŚŝƐƵŶƐƚĂŶĚĂƌĚŝǌed method of BP measurement led to the opportunity to study men 
with an assumed hyper-reactivity to mental stress ΀ϰ͕ ϵ΁͘ dŚĞ ƐĐƌĞĞŶŝŶŐW ĐĂŶ ƚŚƵƐ ŝŶŵĂŶǇ
ways be regarded as a mental stress test. A clear correlation between high screening BP and 
high response to the laboratory mental stress test supports this ΀ϲϴ΁.  
Previously, it has been shown that high screening BP during military draft predicted 
future persistent BP elevation ΀ϴϭ͕ ϴϮ΁͘ ,ŽǁĞǀĞƌ͕ ƚŚĞ W ǀĂůƵĞƐǁĞƌĞ ƚŚĞŶ ĐŽŶĨŝƌŵĞĚ ďĞĨŽƌĞ
follow-up, and not based on a single measurement like in the present study. Consequently, 
those results may rather be viewed as tracking, than as an indication of hyper-reactivity being a 
ƉƌĞĚŝĐƚŽƌ ŽĨ ĨƵƚƵƌĞ ,d͘ EĞǀĞƌƚŚĞůĞƐƐ͕ Ă ŵĞƚĂ-ĂŶĂůǇƐĞƐ ĨƌŽŵ ϮϬϭϬ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ Ă ŐƌĞĂƚĞƌ
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cardiovascular response to acute mental stress has an adverse effect on future cardiovascular 
ƌŝƐŬƐƚĂƚƵƐ͕,dŝŶƉĂƌƚŝĐƵůĂƌ΀ϴϯ΁͘dŚĞƐĞĂƐƐŽĐŝĂƚŝŽŶƐǁĞƌĞƐƚƌŽŶŐĞƌĂŵŽŶŐŵĞŶƚŚĂŶǁŽŵĞŶ͕ŝŶ
younger age groups, and in those with longer follow-up periods. In what way hyper-reactivity 
influences ŽŶ ĨƵƚƵƌĞ ĂŵŽƵŶƚ ŽĨ d Žƌ ŝŶƐƵůŝŶ ƐĞŶƐŝƚŝǀŝƚǇ ŝƐ ŶŽƚǁĞůů ĚĞƐĐƌŝďĞĚ͘KƵr research 
group has shown that elevated ĂĚƌĞŶĂůŝŶĞƌĞƐƉŽŶƐĞƚŽD^dǁĂƐĂŶĞŐĂƚŝǀĞƉƌĞĚŝĐƚŽƌŽĨĞ͘Ő͘D/
and waist circumference ΀ϭϮ΁, but no significant association was found to future insulin 
sensitivity ΀ϭϭ΁͘ ,Žǁ ƚŚĞ ĂƐƐŽĐŝĂƚŝŽŶƐ ǁĞƌĞ ĂĐĐŽƌĚŝŶŐ ƚŽ Śigh or low screening BP was not 
evaluated in these studies. 
Both at baseline and at follow-up, BP measurements were conducted only on one 
occasion, which is not according to guidelines. Still, in Paper I absolute values were not 
evaluated, only BP groups. ŶĚ͕ƐŝŶĐĞŽŶůǇϮϱйŽĨƉĂƌƚŝĐŝƉĂŶƚƐŚĂǀŝŶŐŵĂƐŬĞĚ,dĚŝƐƉůĂǇĞĚƉre-
hypertensive BP values, we find it unlikely that measurements on additional days would have 
had a great influence on the results. 
dŚĞ ƉƌĞƐĞŶƚ ǁŽƌŬ is based on five previous studies being conducted by four medical 
doctors during a time-span of 12 years. Several important baseline examinations are dependent 
on the examiner. Especially in a cohort with a predominance of men that may be particularly 
hyper-reactive, different examiners could influence on the results of measurements such as BP, 
,Z͕ ŝŶƐƵůŝŶ ƐĞŶƐŝƚŝǀŝƚǇ ŵĞĂƐƵƌĞĚ ďǇ ŐůƵĐŽƐĞ ĐůĂŵƉ͕ ĂŶĚ ƚŚĞ D^d͘ As discussed in Paper I, 
different examiners has probably been of importance to baseline BP measurement. Still, our 
results show that screening BP (Paper IͿ͕ ĨĂŵŝůǇ ŚŝƐƚŽƌǇ ŽĨ ,d͕ ƚƌŝŐůǇĐĞƌŝĚĞƐ ;Paper IIͿ͕ ĨĂŵŝůǇ
ŚŝƐƚŽƌǇ ŽĨ ĚŝĂďĞƚĞƐ͕ D/ ĂŶĚ ,> ĐŚŽůĞƐƚĞƌŽů ;Paper IIIͿ ƉƌĞĚŝĐƚĞĚ ĨƵƚƵƌĞŵĂƐŬĞĚ ,d͕ ŝŶƐƵůŝŶ
ƐĞŶƐŝƚŝǀŝƚǇĂŶĚd͕ ƌĞƐƉĞĐƚŝǀĞůǇ͘ǆĐĞƉƚ ĨŽƌƐĐƌĞĞŶŝŶŐW͕ĂƐĂůƌĞĂĚǇĚŝƐĐƵƐƐĞĚ͕ŶŽŶĞŽĨ ƚŚŽse 
predictors are influenced by the examiner. 
The glucose clamp 
dŚĞƌĞǁĞƌĞ ƐĞǀĞƌĂů ĚŝĨĨĞƌĞŶĐĞƐďĞƚǁĞĞŶ the baseline and follow-up clamp procedures 
(Table 1Ϳ͘ ƚ ďĂƐĞůŝŶĞ͕ ϯϵ ŵĞŶ ǁĞƌĞ ĐůĂŵƉĞĚ ĨŽƌ ŽŶůǇ ϵϬ ŵŝŶƵƚĞƐ͕while the remaining ϲϰ
participants were clamped ĨŽƌ ϭϮϬ ŵŝŶƵƚĞƐ͘ /Ŷ ŵĞŶ ďĞŝŶŐ ƐƵďũĞĐƚĞĚ ƚŽ the latter, insulin 
ƐĞŶƐŝƚŝǀŝƚǇǁĂƐƐŝŐŶŝĨŝĐĂŶƚůǇůŽǁĞƌĂĨƚĞƌϵϬŵŝŶƵƚĞƐƚŚĂŶĂĨƚĞƌϭϮϬŵŝŶƵƚĞƐ͕ďŽƚŚĂƚďĂƐĞůŝŶĞĂŶĚ
at follow-ƵƉ͘dŚĞƌĞĨŽƌĞ͕ǁĞƵƐĞĚŽŶůǇϭϮϬŵŝŶƵƚĞƐĐůĂŵƉĨƌŽŵďĂƐĞůine. 
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A heating sleeve used to arterialize blood during the glucose clamp was used in all 
ďĂƐĞůŝŶĞƐƚƵĚŝĞƐĞǆĐĞƉƚŽŶĞ͘,ĂŶĚ-warming has been shown to increase insulin sensitivity ΀ϴϰ΁. 
Since a heating ƐůĞĞǀĞ ǁĂƐ ƵƐĞĚ ŝŶ Ăůů ƚŚĞ ϭϮϬ-minute clamps, hand-warming was of no 
importance when gathering baseline studies, where the ϵϬ-minute clamp was excluded. 
,ŽǁĞǀĞƌ͕ǁĞĂůƐŽĂƐƐĞƐƐĞĚ tracking of insulin sensitivity, comparing baseline values, measured 
with a heating sleeve, to follow-up values measured without a heating sleeve. If insulin 
sensitivity was artificially increased due to hand-warming at baseline, the tracking coefficient 
could be underestimated. Still, the value would be considerably lower than for the other 
cardiovascular risk markers. Moreover, the results are in line with previous studies ΀ϯϳ-ϯϵ΁, 
finding low tracking coefficients for insulin sensitivity among young people, again supporting 
our results. 
Another difference between baseline and follow-up glucose clamps was type of insulin 
used͘ dŽ ĞǆƉůŽre any potential clinical differences between the two types of insulin, a 
methodological randomized double-blinded crossover study was performed ;ƵŶƉƵďůŝƐŚĞĚͿ. 
&ŽƵƌƚĞĞŶƉĂƌƚŝĐŝƉĂŶƚƐ;ϭϯŵĞŶͿ͕ŵĞĂŶĂŐĞϯϴ;цϳͿǇĞĂƌƐĂŶĚŵĞĂŶ'ZǁŝƚŚ,ƵŵĂůŽŐϲ͘ϵϲ;ц
ϯ͘ϴϴͿŵŐͬŬŐďŽĚǇǁĞŝŐŚƚͬŵŝŶ͕ǁĞƌĞĞǆĂŵŝŶĞĚϴ;цϮͿĚĂǇƐĂƉĂƌƚ͘tŝƚŚĂŶ/ǀĂůƵĞŽĨϬ͘ϵϮ;ϵϱ% 
/сϬ͘ϳϰ-Ϭ͘ϵϳͿ͕ǁĞĐŽŶĐůƵĚĞĚƚŚĂƚƚŚĞƚǁŽƚǇƉĞƐŽĨŝŶƐƵůŝŶĐŽƵůĚďĞƵƐĞĚŝŶƚĞƌĐŚĂŶŐĞĂďůǇ͘ 
Blood pressure measurements 
Another methodological difference between baseline and follow-up examinations was 
measurement of office BP. As discussed in Paper I, the examiners did not abstain from talking 
with the participants during BP measurements at baseline. Assuming a predominance of hyper-
reactive men, this is probably an impoƌƚĂŶƚƌĞĂƐŽŶĨŽƌϳϬйŽĨƚŚĞŵĞŶŚĂǀŝŶŐǁŚŝƚĞ-ĐŽĂƚ,dĂƚ
baseline, and the apparent reduction of office BP between baseline and follow-up. 
Subsequently, tracking of office BP in Paper II must be seen in light of this. We observed a 
decrease, with tracking cŽĞĨĨŝĐŝĞŶƚĨŽƌƐǇƐƚŽůŝĐWŽĨϬ͘ϲ͕ǁŚŝůĞŽƚŚĞƌƐŚĂǀĞĨŽƵŶĚŝŶĐƌĞĂƐĞŝŶW
ǁŝƚŚƚƌĂĐŬŝŶŐĐŽĞĨĨŝĐŝĞŶƚďĞƚǁĞĞŶϬ͘ϯϵĂŶĚϬ͘ϱϰ΀ϯϳ͕ϯϵ͕ϴϱ͕ϴϲ΁.  
/ŶEŽƌǁĂǇ͕ƉƌĞǀĂůĞŶĐĞŽĨ,dĂŵŽŶŐŵĞŶĂŐĞĚϯϬ-ϯϵǇĞĂƌƐ ŝŶϭϵϵϱ-ϭϵϵϳ;,hEdϮͿǁĂƐ
Ϯϵ͘ϱ%, with great variance accordiŶŐƚŽĨĂŵŝůǇŚŝƐƚŽƌǇŽĨ,dĂŶĚD/΀ϴϳ΁͘&ŝŶĚŝŶŐƚŚĂƚϲϱйŽĨ
ƚŚĞŵĞŶǁŝƚŚŚŝŐŚƐĐƌĞĞŶŝŶŐWůĂƚĞƌǁĞƌĞĚŝĂŐŶŽƐĞĚǁŝƚŚŵĂƐŬĞĚ;ϰϳйͿŽƌƐƵƐƚĂŝŶĞĚ;ϭϴйͿ,d
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ŝŶĚŝĐĂƚĞƐƚŚĂƚƚŚŝƐŝƐŶŽƚĂƌĞƉƌĞƐĞŶƚĂƚŝǀĞŐƌŽƵƉƌĞŐĂƌĚŝŶŐWĚĞǀĞůŽƉŵĞŶƚ͘/ŶƚŽƚĂů͕ŽŶůǇϭϰŽĨ
ϭϬϬ ŚĂĚ ƐƵƐƚĂŝŶĞĚ ,d Ăƚ ĨŽůůŽǁ-up. ,ŽǁĞǀĞƌ͕ ĐŽŵƉĂƌĞĚ to prevalence in men with 
ĂƉƉƌŽǆŝŵĂƚĞůǇ ƚŚĞ ƐĂŵĞĚĞŐƌĞĞŽĨ ĨĂŵŝůǇŚŝƐƚŽƌǇŽĨ,dĂŶĚD/-level, the numbers are quite 
similar ΀ϴϳ΁.  
Questionnaires 
We have no knowledge of the participants’ lifestyle between baseline and follow-up. In 
ƚŚĞƋƵĞƐƚŝŽŶŶĂŝƌĞƐƚŚĞĂŶƐǁĞƌƐǁĞƌĞŽŶůǇŝŶƌĞŐĂƌĚƚŽƚŚĞůĂƐƚϭϮŵŽŶƚŚƐ͘,ŽǁĞǀĞƌ͕ƐŝŶĐĞƚŚĞ
last year’s lifestyle to a high degree will be reflected in the variables examined, we believe our 
results are valid. Another challenge is the use of information on family history of diabetes and 
,d͘&ŝƌƐƚŽĨĂůů͕ǁĞǁŽƵůĚƉƌĞĨĞƌƚŽŚĂǀĞdata on family history collected at baseline, though this 
may not be of great importance ΀ϰϱ΁. Secondly, we have no first-hand confirmation, or 
documentation, on parental disease. Finally͕ǁĞĐĂŶĂƐƐƵŵĞƚŚĂƚŶŽƚĂůůĂƌĞĂǁĂƌĞŽĨƚŚĞŝƌ,dŽƌ
ĚŝĂďĞƚĞƐ͕ŐŝǀĞŶĂƌĞůĂƚŝǀĞůǇŚŝŐŚŶƵŵďĞƌŽĨƉĞŽƉůĞďĞŝŶŐƵŶĚŝĂŐŶŽƐĞĚ͘,ŽǁĞǀĞƌ͕ĂůůƌĞƉŽƌƚƐŽŶ
family history ŽĨĚŝĂďĞƚĞƐǁĞƌĞĐŽŶĨŝƌŵĞĚ ŝŶ ƚŚĞǀĂůŝĚĂƚŝŽŶƋƵĞƐƚŝŽŶŶĂŝƌĞƐ͘dŚƌĞĞƉĂƌƚŝĐŝƉĂŶƚƐ
initially answering they had a first-ĚĞŐƌĞĞ ƌĞůĂƚŝǀĞ ǁŝƚŚ ,d ƌĞƉůŝĞĚ ƚŚĞǇ ŚĂĚ ŶŽŶĞ ŝn the 
validation questionnaire. 
Computed tomography 
/ŶƚŚĞ&ƌĂŵŝŶŐŚĂŵ,ĞĂƌƚ^ƚƵĚǇƚŚĞĂƵƚŚŽƌƐƐŚŽǁĞĚƚŚĂƚdŵĞĂƐƵƌĞŵĞŶƚƐŽĨ^dĂŶĚ
sdĂƌĞĂŽďƚĂŝŶĞĚĂƚůĞǀĞů>ϯͬϰ were most strongly associated with simultaneous assessment of 
ǀŽůƵŵĞƐŽĨ^dĂŶĚsd͘DĞĂƐƵƌĞŵĞŶƚƐĂƚ ƚŚŝƐ ůĞǀĞůǁĞƌĞalso most strongly associated with 
cardiometabolic risk factors ΀ϴϴ΁. We therefore chose to measure at level >ϯͬϰ in our protocol. 
 dŚĞƌĞŚĂƐďĞĞŶĐŽŶĨƵƐŝŽŶĂƌŽƵŶĚƚŚĞŶŽŵĞŶĐůĂƚƵƌĞŽĨƚŚĞůĂǇĞƌĚŝǀŝĚŝŶŐƚŚĞƐƵƉĞƌĨŝĐŝĂů
and deep layer of the abdominal subcutaneous fat tissue ΀ϴϵ΁͘dŚĞŵŽƐƚǁŝĚĞůǇƵƐĞĚƚĞƌŵƐĂƌĞ
Scarpa’s ĨĂƐĐŝĂ͕ŽůůĞƐ͛ĨĂƐĐŝĂ͕ĂŵƉĞƌ͛ƐĨĂƐĐŝĂĂŶĚƚŚĞƐƵƉĞƌĨŝĐŝĂůĨĂƐĐŝĂ͘ŝĨĨĞƌĞŶƚƚĞƌŵƐĂƌĞƵƐĞĚ
for the same structure, and vice versa. We therefore chose to name it a membranous layer, in 
accordance with a recent recommendation ΀ϴϵ΁. 
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Statistics 
ƵĞƚŽƚŚĞ relatively low number of participants, interpretation of the analyses should 
be done with caution. Some baseline variables had missing values mainly due to different 
protocols between the five studies at baseline. In addition, sub-division of the material 
(according to screening BP in Paper I and to parental diabetes in Papers II and IIIͿ creates even 
smaller groups, making interpretation even more vulnerable for type II errors. Moreover, a 
potentially very interesting analysis, multivariable regression analysis in the group with family 
ŚŝƐƚŽƌǇ ŽĨ ĚŝĂďĞƚĞƐ͕ ĐŽƵůĚ ŶŽƚ ďĞ ƉĞƌĨŽƌŵĞĚ͘ dŚŝƐ ǁŝůů ďĞ ĨƵƌƚŚĞƌ ĂĚĚƌĞƐƐĞĚ ŝŶ ŝƐĐƵƐƐŝŽŶ ŽĨ
results. 
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Discussion of results 
Masked HT 
The causes of masked HT are unclear [20]. However, it is likely that masked and 
sustained HT have several mechanisms in common, since development of sustained HT often 
follows masked HT [26, 28, 29, 90]. The central nervous system, the renin-angiotensin-
aldosterone system, increased adrenaline sensitivity, inflammation, endothelial dysfunction and 
arterial stiffness are all suggested to be involved [4, 20, 91]. 
It also seems that some mechanisms behind masked HT and sustained elevated BP differ. 
For example, seemingly contradictory, family history of HT, which is well known to increase the 
risk of sustained HT, is not necessarily closely related to hyper-reactivity [92, 93], and was not 
related to masked HT (data not shown). On the other hand, 90% of the participants with family 
history of diabetes had high screening BP (Paper II). Moreover, chronic elevation of sympathetic 
activity has been associated with pre-hypertension and sustained HT [7, 94], while the 
intermediate elevation, the hyper-reactivity, is more characteristic in those with masked HT.  
Having pre-hypertensive BP values is maybe the most established marker for concurrent 
masked HT [19]. The group with high screening BP had high office BP at baseline, but not at 
follow-up. The elevated office BP at baseline is interpreted as a consequence of measurement 
method, as discussed in Paper I, and not an indication of masked HT. The question is then why 
men with masked HT had such low office BP values at follow-up? According to guidelines, these 
men would not have been recommended ambulatory BP measurements, and thus remained 
undiagnosed [19]. One reason could be that the group with high screening BP may still have an 
elevated stress response [13], but in contrast to what has been found in pre-hypertensive men 
[7, 68, 95], they might not have a high stress level during rest [13]. The fact that we emphasized 
a relaxed atmosphere during BP measurements may thus have been particularly important in 
these hyper-reactive men. 
There are to our knowledge no prior studies on longitudinal predictors of masked HT. 
Mental stress, measured as job strain, has been associated with masked HT in cross-sectional 
studies [20]. In many regards, military screening, consisting of a whole day of physical and 
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psychological evaluation, can be viewed as a mental stress test. Thus, our results indicate that 
mental stress also is a long-term predictor of masked HT. Moreover, our research group has 
previously found that cardiovascular and sympathoadrenal reactivity to mental stress is a rather 
stable feature [13]. Taken together, this supports the validity of our findings. Our results are 
also in agreement with the conclusions in a meta-analysis from 2010, where incident HT was 
predicted by greater stress reactivity [83]. The authors suggested that the hyper-reactive 
response, with repeated BP elevations, with time could lead to persistent elevation in BP. The 
BP development will then depend on daily life stress exposure. An alternative, or additional, 
explanation is that the cardiovascular response is a marker of an underlying process which 
simultaneously can lead to masked HT. The observed BP development supports the first theory, 
and as will be addressed later, several of our findings support the suggestion of an underlying 
process. 
There is a cross-sectional association between the level of catecholamines during mental 
stress and screening BP [4]. One might deduce that the high screening BP is a reflection of the 
catecholamine level, and hence the driving force behind the high BP the following years. 
However, one would then expect that not only high screening BP is related to future masked HT, 
but also the catecholamine level during mental stress. That was not the case in our trial. This 
brings us back to the theory of an underlying process which gives rise to elevated 
catecholamines during stress, and in parallel (not necessarily as a consequence of) leads to high 
screening BP. This process could again partly explain a high prevalence of masked HT. Some of 
the findings in Paper III also support this theory. Adrenaline during MST correlated negatively 
with future amount of AAT. Still, men with high screening BP had higher BMI and larger amount 
of AAT in all three compartments, though the differences did not reach level of significance 
(unpublished data). This suggests that the high screening BP is not caused by, but rather co-
occurs with high levels of catecholamines. 
To our surprise, we observed a reduction in office BP between baseline and follow-up 
examinations. As discussed in Paper I, there are several potential explanations. Though the 
statement by Kaplan is dated back to 1998, it may still be relevant; “that BP measurement is 
likely the procedure of greatest importance that is performed in the sloppiest manner” [96]. 
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However, performing BP measurements that are not according to guidelines may actually 
reveal information otherwise hidden. These measurements may also be valuable, if correctly 
interpreted and handled. The importance of measurement methods is emphasized both in 
major guidelines, and in numerous articles [19, 97, 98]. Interestingly, there have been no 
studies supporting the recommendation of resting a few minutes prior to office BP 
measurement [99], which was the main difference between baseline and follow-up 
measurements in the present study. Possibly, the decrease in BP during rest may be more 
evident in people prone to high BP. In a study of untreated hypertensive patients, researchers 
have shown that BP fell progressively during rest (11.6/4.3 mmHg), especially the first 10 
minutes [100]. Similarly, BP-lowering was observed after 15 and 30 minutes of rest in men with 
high screening BP [4]. In a population with mean systolic BP of 135.7 mmHg, the fall in BP was 
10.3/0.8 mmHg for men, but whether the reduction was similar in all BP categories is uncertain 
[101]. In the present study, office BP at baseline was progressively higher in the groups who 
had normotension, masked HT and sustained HT at follow-up. A BP measured without the 5 
minutes of rest may thus tell us more about future BP than a standardized measurement 
according to guidelines, as indicated before [10]. An important advantage of the recommended 
rest prior to measurement is of course a greater standardization. Immediate BP measurement, 
without rest, will probably convey an elevated incidence of white-coat HT and an increased 
need for out-of-office BP measurements. On the other hand, if the concomitant effect is 
discovering masked HT, it may be worth considering doing both. 
 
Insulin sensitivity 
The sympathetic nervous system has not only been linked to masked HT but also to 
insulin sensitivity [102]. We have previously observed that the adrenaline level during mental 
stress is related to insulin sensitivity, but only in cross-sectional studies [5, 103, 104]. When 
examining whether baseline catecholamines, during rest or mental stress, predicted future 
insulin sensitivity, we found no association in the present study. This is in line with previous 
results from our research group, where only catecholamines during the cold pressor test, not 
during the MST, predicted future insulin sensitivity [11]. As suggested in the previous section, it 
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seems like an underlying process leads to both high screening BP and low insulin sensitivity, 
independent of high catecholamines during mental stress. 
 Most studies have shown that family history of HT has a negative influence on glucose 
metabolism, [42, 43, 105-108], though not all [109]. Suggested mechanisms are oxidative stress, 
hypomagnesaemia [105], and low adiponectin level [106, 110]. The latter has in addition been 
observed among those with a family history of diabetes [111]. Intrauterine environment and 
adipose tissue dysfunction are other potential explanations for lower insulin sensitivity in 
diabetic offspring [45, 112]. Nonetheless, a substantial portion of the risk associated with family 
history of diabetes or HT remains unexplained [45, 105, 113-115]. In our study, family history of 
HT and family history of diabetes correlated to the same extent with insulin sensitivity at 
follow-up, though family history of diabetes has been more strongly associated in previous 
studies [41, 42, 107]. That only family history of HT remained a significant predictor in 
multivariable regression analysis could be due to the relatively low number of participants. 
In men without a family history of diabetes, none of the baseline risk markers remained 
predictors of future insulin sensitivity in the multivariable linear regression analysis. One 
interpretation is that their insulin sensitivity is mainly determined by their concomitant lifestyle 
and metabolic profile. In contrast, baseline risk markers showed a relatively strong correlation 
with future insulin sensitivity in men having a family history of diabetes. In addition, we 
confirmed that these men, at an early age, had a worse cardiovascular profile than men without 
family history of diabetes [116]. Unravelling the causes of DM2 has been a major research focus 
for decades. Most commonly, it is caused by an unhealthy diet and low physical activity leading 
to obesity [47, 117], with the subsequent increased risk of DM2 [118]. Our results support the 
notion that for some individuals, family history of diabetes is mainly accountable for the 
increased risk of DM2 [45, 119]. In the latter case, DM2 can develop also in lean individuals 
[112]. Individuals with a family history of diabetes also seem to have a lower “tolerance” to the 
negative impact from an unhealthy lifestyle [119-121]. Anyhow, the increasing tendency to a 
sedentary lifestyle unfortunately increases DM2 through both these pathways. 
Another potential explanation for the lack of association between baseline risk markers 
and future insulin sensitivity among men without a family history of diabetes is that we did not 
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measure the relevant risk markers. In that case, intrauterine factors or birth weight could be 
potential candidates [44, 122]. Moreover, biochemical markers, like the adipokines leptin and 
adiponectin, or inflammatory mediators, like interleukin 6 and tumor necrosis factor-ɲ͕ǁĞƌĞ
not measured [118, 123]. 
In contrast to our study, insulin resistance has been found to precede an adverse 
cardiovascular risk profile [124]. However, family history was not accounted for, and 
participants were followed for 6 years from the age of 13, a period where insulin resistance 
may have a peak [125]. In a study of children with family history of diabetes, the authors 
suggested that elevated BMI in childhood precedes reduced insulin sensitivity in adolescence, 
which again precedes dyslipidaemia in adulthood [116]. Again, it is uncertain whether these 
results are applicable to other age groups. If our results are confirmed, what reasons could 
there be for men with family history of diabetes to first have a worse cardiovascular risk profile, 
and subsequently lower insulin sensitivity? One theory is that obesity and the increase in other 
cardiovascular risk markers causes the low insulin sensitivity through mechanisms including for 
instance the sympathetic nervous system [46] or adipose tissue dysfunction [54, 126]. The 
latter could also explain the impaired insulin sensitivity in lean offspring of diabetic parents [53, 
112]. Another question then arises; why do men with family history of diabetes have these 
unfavourable metabolic traits? Whether it is caused by intrauterine factors [122], the 
sympathetic nervous system [127], adipose tissue dysfunction [53, 54, 112], inflammation [112], 
or unknown determinants is not clear. Still, it is possible that some of the causal factors also 
induce the relatively high degree of tracking of cardiovascular risk markers in men with, as 
compared to without, family history of diabetes. 
From cross-sectional studies we know that not only the amount of adipose tissue, but 
also its distribution, is of importance when assessing cardiovascular risk. Centrally distributed 
adipose tissue is most strongly associated with low insulin sensitivity [118]. Interestingly, 
researchers recently observed higher waist-hip-ratio (WHR) and HOMA-IR in persons with, as 
compared to without, family history of diabetes, despite equal BMI [112]. In our study, both 
BMI and waist circumference in men with family history of diabetes correlated strongly with 
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future insulin sensitivity. This suggests an early and important role for adipose tissue, which will 
be further discussed in the next section. 
 
Abdominal adipose tissue 
We know that family history of diabetes is negatively associated with cardiovascular and 
metabolic features, including obesity [54], though the mechanisms through which this happens 
remain unclear [45]. The obesity associated with family history of diabetes is primary centrally 
located, i.e. abdominal adiposity [54, 112, 116], and is suggested to be more associated with 
VAT than SAT [54]. It is, however, also linked to SAT, but without further subdivision of the SAT 
compartments [112, 128]. 
The novelty of our study is that family history of diabetes had a greater impact on the 
amount of deep SAT, than on superficial SAT. This has to our knowledge not been examined 
previously. Researchers have found that family history of diabetes is associated with a more 
dysfunctional AAT, linked to metabolically unfavourable traits [53, 54, 112, 128]. Moreover, in 
studies where family history is unaccounted for, deep SAT has been found to be metabolically 
more dysfunctional than superficial SAT [61, 62, 64]. Taken together, these findings increase the 
plausibility of our results. 
There has been increasing attention towards distribution, not only amount, of adipose 
tissue [52, 129-133]. Our findings support the theory of ectopic fat contributing to the 
increased risk of DM2 [54, 134]. Individuals prone to DM2 seem to have an impaired capacity to 
store excess fat in subcutaneous compartments, and rather accumulate visceral fat [134]. 
Unfortunately, the primary distinction has again been made between VAT and SAT, without 
further subdivision of SAT. Thus, the increased risk for e.g. diabetes and HT has been attributed 
to higher VAT, while the role of deep SAT is not particularly appreciated. In a large genetic study, 
where family history was not accounted for, reduced SAT was suggested to be essential to i.e. 
DM2 and HT [123]. If family history of diabetes predominantly leads to increased VAT and deep 
SAT, it could suggest that an impaired ability to store excess fat as superficial SAT is one of the 
mechanisms increasing risk of DM2. 
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We did not examine the biochemical characteristics of the adipose tissue. However, 
several recent papers have shown that family history of diabetes is associated with abdominal 
tissue dysfunction, also in non-obese persons [53, 54, 112, 128]. As the negative impact from 
having a family history of diabetes apparently starts early, adipose tissue dysfunction may be 
one explanation to the high degree of tracking of cardiovascular risk markers that we observed 
in this group (Paper II). 
A second discovery described in Paper III was that in men without a family history of 
diabetes, the cardiovascular risk profile they had 17 years earlier was of less significance to 
future AAT, than among men with a family history of diabetes. This is consistent with our 
findings in Paper II, where baseline risk markers correlated much stronger with future insulin 
sensitivity in men with, as compared to without, a family history of diabetes. It is also in 
agreement with the findings in a large 7-year follow-up study; that there was no reduced risk of 
HT in participants being previously lean [135]. Again, our results imply that the current lifestyle 
(as opposed to their previous lifestyle) has a greater impact on a person’s contemporary risk 
profile among men without a family history of diabetes.  A healthy lifestyle is, of course, also 
important, and probably of even greater importance, when having a family history of diabetes 
[120, 121]. Diabetes can be prevented with interventions counteracting weight gain, also in 
diabetic offspring [53, 136]. Whether response to lifestyle interventions in the latter group is 
more or less effective than among persons without a family history of diabetes, is however not 
agreed on [137-139]. Unfortunately, it does seem like the unfavourable cardiovascular and 
metabolic profile is more predestined among persons with a family history of diabetes. This 
view is supported by studies of adopted children, where no increased risk for DM2 was found 
when the adoptive parents had DM2. On the other hand, an increased risk was found if their 
biological parents had DM2 [140]. 
In addition to family history of diabetes, baseline BMI was a strong predictor of future 
AAT. As mentioned, the link between distribution of adipose tissue and cardiovascular and 
metabolic risk [49, 54, 132], even in lean persons [141], is well described. The distribution of 
adipose tissue may even be of greater importance than obesity per se [49, 142]. One could thus 
argue that using waist circumference, WHR or waist-height ratio (WHtR) would be preferable 
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over BMI [130, 141-143]. In our material there was a distinction according to family history of 
diabetes. Without a family history of diabetes, only BMI correlated with future amounts of AAT, 
and then only the SAT-layers. In men with a family history of diabetes, however, BMI correlated 
with all the AAT layers. WHR did not correlate with any of the layers, while WHtR and waist 
circumference had correlation coefficients between 0.52-0.67 with all three layers. At follow-up, 
on the other hand, all four measures correlated cross-sectionally with the AAT compartments, 
having correlation coefficients between 0.58-0.90, with only minor differences according to 
hereditably (unpublished data). This may indicate that choice of measurement method depends 
on whether it is the current or future risk being assessed, and if the person has a family history 
of diabetes. Differences between different age groups, sexes and ethnicities also need to be 
taken into account [144]. 
The men with a family history of diabetes had strong correlation coefficients between 
baseline variables and future AAT in Paper III. With a larger sample size, a multiple regression 
analysis could have been performed in that group as well. Adrenaline response to mental stress, 
TGs and having a first-degree relative with HT were all highly correlated with future amount of 
AAT in men with a family history of diabetes. Their potential as predictors will therefore be 
discussed below. 
 First, we observed that baseline adrenaline response to mental stress could be a 
negative predictor, especially among men with a family history of diabetes. Offspring of patients 
with DM2 have previously shown an increased resting muscle sympathetic nerve activity 
(MSNA) [127]. Adrenaline response to mental stress in this group is however unknown. The 
relationship between obesity and sympathetic nervous system activity is highly complex, and 
has been investigated for decades [102]. Several follow-up studies have found resting 
noradrenaline to be positively related to weight gain [145, 146], and adrenaline response to 
mental stress as a negative predictor of weight gain [12]. Different methods to assess stress, 
cross-sectional versus longitudinal relationships, resting versus stress-induced and acute versus 
chronic stress, complicate comparison between different studies. If we focus on the adrenaline 
response to mental stress, as was assessed in our study, previous results may not be that 
contradictory after all. In a longitudinal study, adrenaline response during the MST was 
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negatively associated with change in BMI [12]. In a cross-sectional study, obesity was found to 
be associated with a blunted neuroendocrine response to acute mental stress [147]. Our 
research group has in addition found catecholamine response to be a relatively stable feature 
[13]. Taken together, this suggests that adrenaline response to mental stress could have been a 
negative predictor of future AAT in a multivariable analysis, at least in men with a family history 
of diabetes. 
 Secondly, TGs and having a first degree relative with HT were the two remaining 
predictors of insulin sensitivity (Paper II). A possible mechanism behind this finding could 
include adiponectin, which has shown to be reduced in persons with a family history of HT 
[106], and also been associated with increased HDL cholesterol and reduced TGs [148].  It is 
tempting to speculate that with a larger study than ours, TGs and family history of HT could 
have been significant predictors of AAT in men with a family history of diabetes. 
 
Concluding remarks and future perspectives 
When trying to untangle all the information on what precedes the other, follow-up 
studies are preferred over cross-sectional studies. However, one type of study falls between the 
two, namely, cross-sectional studies including participants with a family history of a disease, 
with the assumption that they eventually will develop the disease. As for those with family 
history of diabetes and HT, DM2 will occur in 30-70% [54] and HT in around 35-50% [19, 149], 
respectively. Whether and when the disease develops is influenced by the age of both the 
affected patient and their relative, the relationship between them, and the number of affected 
relatives in the family [45, 105]. Then again, this relatively high hereditability underscores the 
importance of taking family history into account when examining interrelationship and 
development of cardiovascular and metabolic diseases. 
A considerable amount of the associations found in our study seems related to family 
history of diabetes and HT. It is not unlikely that causal mechanisms are different in persons 
with and without a family history of diabetes or HT. Hence, it is unfortunate that family history 
often is unaccounted for. 
40 
 
Family history of HT increases the risk of HT, but is also found to be a risk marker for 
both overweight and insulin resistance [19, 42, 56, 57, 107]. Several studies find that in persons 
with a family history of HT, insulin resistance precedes HT [42, 107]. It has been suggested that 
genes associated with BP regulation might be involved in development of insulin resistance [43]. 
Further, low level of adiponectin, associated with worse insulin sensitivity, has also been found 
in normal weight, normotensive men with a family history of HT [110]. It thus seems like factors 
associated with a family history of HT, and not HT in itself, lead to reduced insulin sensitivity, as 
previously hypothesized [150]. 
Overweight and obesity, and especially abdominal fat, is a major cause of DM2 [117, 
129]. The reduced insulin sensitivity, and in many cases subsequent DM2, is moreover closely 
linked to family history of diabetes. In individuals with a family history of diabetes there is a 
general agreement that adipose tissue dysfunction precedes obesity, or alternatively leads to 
DM2 independent of obesity [53, 54, 126, 128]. In children/adolescents with a family history of 
diabetes in the Bogalusa Heart Study, significantly higher level of BMI and subscapular skinfold 
preceded higher levels of insulin and HOMA-IR, which again preceded dyslipidemia [116]. 
Adipose tissue (dys)function was not measured in that study. We could not do multivariable 
regression analysis in men with a family history of DM2, due to limited number of participants. 
However, in addition to family history of HT, BMI and waist circumference were strongly 
correlated to future insulin sensitivity, and thus in line with these other studies. 
All in all, our results suggest that family history of diabetes is essential. Preferably, we 
should have had a larger study and higher validity on family history data. Still, it is difficult to 
disregard its great influence. Ninety per cent of the men with a family history of diabetes had 
high screening BP, suggesting a potential role in the development of masked HT. None of the 
baseline risk markers predicted future insulin sensitivity in Paper II unless the men had a family 
history of diabetes. Finally, family history of diabetes had a strong association with future AAT. 
The latter may be a key to the associations, given the role of adipose tissue dysfunction. 
Although adipose tissue (dys)function was not measured in our study, it could potentially 
be the underlying process explaining nearly all our findings. Many factors are associated with 
adipose tissue dysfunction, and one of them is of particular interest, namely adiponectin. This 
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protein, mainly secreted by adipose tissue is highly heritable, and is in addition to the obvious 
relation to AAT, correlated to insulin sensitivity, HT and dyslipidemia [151-153]. Meta-analyses 
have shown controversial results as to whether adiponectin level is positively, indifferently or 
negatively associated with cardiovascular disease [154]. However, in persons without 
established cardiovascular disease, there is a general agreement on the beneficial role of 
adiponectin in regard to cardiovascular and metabolic diseases [148, 153, 155]. 
 Some researchers even suggest that adiponectin may be involved in the reduced insulin 
sensitivity associated with parental diabetes and parental HT [106, 156, 157]. This may thus be a 
potential explanation to our observed group-differences. Adiponectin is also associated with 
lower TG level and higher HDL level [123, 148, 158], and could thus partly explain their 
predictive role on insulin sensitivity and amount of AAT in Papers II and III, respectively. As 
presented in Paper III, the dysfunctional AAT related to family history of diabetes is probably 
related to both VAT and deep SAT. Family history of diabetes has been shown to be associated 
with reduced adiponectin in many [111, 156-160], though not all studies [161, 162]. Further, 
family history of diabetes is associated with a worse metabolic and cardiovascular profile. Taken 
together, this supports our finding of family history of DM2 being more strongly associated with 
the metabolically unfavourable VAT and deep SAT, than to superficial SAT. 
It is difficult to deduce which order of appearance the risk markers have from our 
material. Firstly, because of the methodological challenges related to office BP measurement, 
and few ambulatory measurements at baseline. Secondly, because our participants are still 
young, and relatively few have developed HT or insulin resistance. Thirdly, we measured insulin 
sensitivity by clamp, where there is no consensus on cut off values for insulin resistance [163]. 
However, only 14 participants had developed sustained HT at follow-up, while insulin sensitivity 
decreased significantly from baseline, which makes it more likely that insulin resistance 
precedes HT. 
Factors associated with high screening BP, which is different from the adrenaline 
response to MST, seems to predict both masked HT and reduced insulin sensitivity, in addition 
to increased amount of AAT. These unfavorable features are also associated with family history 
of diabetes, and for insulin sensitivity and AAT, with family history of HT as well. 
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As for uncovering masked HT, it would be interesting to do a large study where BP was 
measured both with and without the 5 minutes of rest. Thereafter, by means of ambulatory BP 
measurement, one could evaluate the potential of revealing masked HT by non-resting BP 
measurement. 
There are potentially many ways to slow down, or hopefully turn, the unfortunate 
increase in cardiovascular and metabolic diseases. However, to do so, it is imperative to know 
the order of appearance of the different cardiovascular and metabolic risk markers. In addition, 
creating tools to identify individuals with increased risk at an early age increases the 
opportunity to start with preventive measures. This is even more important when it comes to 
risk markers that do not give any symptoms until the disease manifests, or even years later. 
Dealing with this complex web of interactions, with many unknown factors, large studies 
are necessary. In parallel, progressively more advanced methods in genetic studies provide new 
knowledge. In clinical investigations, it seems appropriate to recommend taking into account 
both family history of HT and family history of DM2. 
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CONCLUSIONS 
x We found that having high screening blood pressure at the military draft was a strong 
predictor for future masked hypertension in young men. Catecholamine levels were not 
associated with future masked hypertension (Paper I).  
 
x Baseline triglycerides and family history of hypertension were found to predict future 
insulin sensitivity, a result mainly driven by men with a family history of diabetes. 
Baseline body mass index did not predict future insulin sensitivity. Moreover, clamp-
derived insulin sensitivity was not a long-term stable feature (Paper II). 
 
x Baseline body mass index and family history of diabetes were found to be positive 
predictors of future amount of abdominal adipose tissue, while HDL cholesterol 
remained a negative predictor. Baseline risk markers were further found to be stronger 
associated with amount of abdominal adipose tissue in men with, as compared to 
without, a family history of diabetes (Paper III). 
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Spørreskjema om helsetilstand og risikofaktorer for hjerte- og karsykdom 
 
Hensikten med dette spørreskjema er å skaffe informasjon om din helsetilstand og 
eventuelle risikofaktorer for hjerte- og karsykdom hos deg. Det er viktig at du leser 
spørsmålene grundig, og svarer på alle spørsmålene (plass til kommentarer på s. 10). 
 
Generell informasjon 
 
1. Hvilken sivilstand har du nå? 
 
Gift/samboer  Separert /skilt 
 
Enkemann Enslig 
 
Annet                      beskriv:______________________________________ 
 
          Antall barn: ______ 
 
 
2. Hvilken utdannelse har du? (Sett kun ett kryss for den høyeste utdannelsen du har      
     fullført. Kryss også av for den utdannelsen du eventuelt holder på med.) 
        Fullført  Holder på med 
 
9-årig grunnskole  
 
1-2-årig videregående   
   
Videregående yrkesfaglig  
  
3-årig videregående allmennfaglig, gymnas  
  
Distriktshøyskole, universitet inntil 4 år 
 (cand. mag., sykepleier, lærer, ingeniør)           
 
Universitet, høyskole, mer enn 4 år  
(hovedfag, embetseksamen) 
   
Annen utdannelse:__________________________   
 
Arbeid 
 
 
 
 
 
 
 
   
3. Er du i inntektsgivende arbeid? 
Ja, full tid
 
Ja, deltid: _________%
 
Nei 
AWWE/y
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      4. 
 
 
 
      
      5. 
 
            Ja         Nei 
       Sykepenger (er sykemeldt)    Hvis ja, fra dato:________ 
 
 Arbeidsavklaringspenger     Hvis ja, fra dato:________ 
 
 Uførepensjon       Hvis ja, fra dato:________  
 
 Dagpenger under arbeidsledighet    Hvis ja, fra dato:________ 
 
 Sosialhjelp/stønad      Hvis ja, fra dato:________ 
 
 Annet, beskriv:______________     Hvis ja, fra dato:________ 
 
 
           Ja         Nei 
     6. Har du skiftarbeid, nattarbeid  
          eller går vakter? 
 
 
     7. Hvis du er i lønnet eller ulønnet arbeid, hvordan vil du beskrive arbeidet ditt? 
         (sett et kryss ved det svaralternativ som passer best) 
 
         For det meste stillesittende arbeid? 
         (f.eks. skrivebordsarbeid, studier) 
 
         Arbeid som krever at du går mye? 
         (f.eks. ekspeditørarbeid, lett industriarbeid) 
 
         Arbeid der du går og løfter mye? 
         (f.eks. postbud, pleier, bygningsarbeid) 
 
         Tungt kroppsarbeid? 
         (f.eks. skogsarbeid, jordbruksarbeid, bygningsarbeid)    
 
 
 
 
 
 
 
Tenk på den virksomhet du har arbeidet i lengst tid siste 12 mnd; hvilket yrke/tittel 
  
hadde du på dette arbeidsstedet:______________________________________ 
Mottar du for tiden noen av følgende ytelser?    
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     8. Hvordan stemmer følgende beskrivelser av din arbeidssituasjon. (Sett kun ett             
         kryss for hver linje.) 
      stemmer        stemmer stemmer ikke stemmer ikke 
 ganske  særlig bra i det hele tatt 
 bra 
  
           Jeg har fysisk tungt arbeid  
 
Jeg har et stressende eller  
masete arbeid    
 
Jeg lærer mye i arbeidet mitt    
 
      
          Arbeidet innebærer at jeg gjør de  
samme tingene om og om igjen    
 
Arbeidet mitt krever stor  
arbeidsinnsats 
    
Jeg har muligheten til selv å  
bestemme hvordan arbeidet  
skal utføres 
        
Det er godt samhold på  
arbeidsplassen 
   
Jeg trives i arbeidet mitt    
 
 
 
  Fysisk aktivitet 
 
   9. Hvor lang tid bruker du til sammen daglig foran dataskjerm?  
       (Sett 0 hvis du ikke bruker data) 
 
       I arbeid _____ timer    På fritiden _____ timer   
 
 
 
  10. Hvor mange timer ser du på TV /DVD/spiller PC-spill daglig? 
 
        < 1 time   4-6 timer 
 
 
        1-3 timer  > 6 timer 
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11. Hvordan har din fysiske aktivitet i arbeidstiden vært i det siste året?  
       (Tenk deg et ukentlig gjennomsnitt for året, ikke regn med arbeidsvei) 
        Timer per uke 
      _____________________________________ 
      Ingen     <1 time        1-2 t         3-6 t       7-10 t      11-20 t >20 t 
        
 
Lett aktivitet (ikke svett/andpusten) 
 
Moderat aktivitet 
 
Hard fysisk aktivitet (svett/andpusten) 
 
 
   12. Hvordan har din fysiske aktivitet i fritiden vært det siste året?  
       (Hvis stor variasjon mellom sommer og vinter, ta et gjennomsnitt, arbeidsvei regnes     
       som fritid)      Timer per uke 
      _____________________________________ 
      Ingen       <1 time      1-2 t   3-6 t 7-10 t 11-20 t      >20 t 
 
Lett aktivitet (ikke svett/andpusten) 
 
Moderat aktivitet 
 
Hard fysisk aktivitet (svett/andpusten) 
 
Sykdommer i din nærmeste familie  
 
 
 
Mor Far          Bror Søster   Ingen Vet ikke Hvis ja, alder ved sykdom 
 
 
 __________ 
 
Hypertensjon:       __________  
 
 __________ 
 
 __________ 
 
 
  __________ 
  
 
   __________ 
 
 
 
Beskriv: _______________________________________________________________________ 
 
13. Kryss av for de slektninger som har eller har hatt noen av sykdommene: 
Hjerneslag eller hjerneblødning: 
 
 Sukkersyke (diabetes):  
Andre (f.eks. ”røykeben”): 
Beskriv nedenfor. 
 Hjerteinfarkt:
 
 Blodpropp utenom i hjerte og 
 hjerne. Beskriv nedenfor. 
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Tidligere sykdommer 
 
 
 
         Ja  Nei Usikker (beskriv) 
 
 :_____________ 
 
 
 :_____________ 
 
 
 :_____________ 
 
 
 
 
 
 
 
 
 
 
__________________________________________________________________       
 
__________________________________________________________________      
 
    16. Har du vært innlagt på sykehus?  
 
 Ja     Nei 
  
 Dersom ja, når og av hvilke grunn? 
 
Beskriv: ____________________________________________________________      
 
Aktuelle sykdommer 
 
 
 
 
 
 
 
Beskriv: ____________________________________________________________ 
 
    
 
 
17. Er du for tiden frisk (bortsett fra eventuelle kroniske tilstander)?
 
Hvis du svarte nei; hva feiler det deg?
 
14. Har du tidligere fått påvist noen av følgende sykdommer/tilstander?  
Høyt blodtrykk (hypertensjon): 
 
Hvis ja, når:______________
 
Sukkersyke (diabetes): 
 
Hvis ja, når:______________ 
Høyt kolesterol: 
 
Hvis ja, når?_____________
15. Har du (hatt) andre langvarige, eller alvorlige tilstander/sykdommer? 
Ja
 
Nei
 
Hvis du svarte ja; hvilke(n) sykdom(mer) dreier det seg om ?
 
Ja
 Nei
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Medikamenter  
 
 
 
 
 
 
 
Preparat:______________________ styrke:_________________ antall:_________ 
 
Preparat:______________________ styrke:_________________ antall:_________     
 
Preparat:______________________ styrke:_________________ antall:_________ 
 
 
              Ja  Nei  
 19. Bruker du andre medisiner av og til?     
       (f.eks. Valium, Paracet, Ibux) 
            
          Hvis du svarte ja; hvilke(n) medisin(er) bruker du? 
 
    Nesten daglig Noen ganger i uken  Noen ganger i mnd.  Sjelden 
           
Preparat:_____________ 
 
Preparat:_____________      
 
Preparat:_____________ 
 
 
                      Ja                 Nei 
 
 
 
 
 
 
 
 
Preparat:______________________ styrke:________periode:_________________ 
 
Preparat:______________________ styrke:________periode:_________________     
 
Preparat:______________________ styrke:________periode:_________________ 
 
 
 
 
  18. Bruker du noen form for medisiner fast?
 
Hvis du svarte ja; hvilke(n) medisin(er) bruker du? 
20. Har du tidligere brukt andre medisiner i mer enn 3 mnd sam- 
     menhengende, som du ikke har nevnt ovenfor? 
 
      Hvis ja; hvilke(n) medisin(er) brukte du? 
Ja
 
Nei
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21. Har du brukt vitaminer, mineraler, kosttilskud eller helsekost siste året? 
 
    Ja Nei     Daglig 4-6 x pr.uke 1-3 x pr.uke   <1 x pr. uke 
        
   Vitaminer Hvilke:_______________ 
 
   Mineraler    Hvilke:_______________   
 
 Kosttilskud Hvilke:_______________ 
   (f. eks. tran) 
 
   Helsekost     Hvilke:_______________ 
 
 
Nytelsesmidler 
 
                      Ja                Nei Hvis nei, gå til pkt. 29 
 
 
                                             Av og til            
 
           
    24. Hvis du helt har sluttet å røyke, hvor gammel var du da du sluttet? :_________år                        
     
           
 
 
 1-5   16-20   30 + 
  
 6-10 21-25 
 
 11-15              26-30  
     
          Hvis av og til, hvor mange per uke:_______ stk 
 
    26. Hvis du har røykt tidligere; hvor mange sigaretter røykte du vanligvis     
          daglig? 
 
           1-5   16-20   30 + 
  
 6-10 21-25 
 
 11-15              26-30  
 
          Hvis av og til, hvor mange per uke:_______ stk 
    
 
 
  22. Har du noen gang røykt?
 
 
     23. Røyker du nå? 
        25. Hvis du røyker fremdeles, hvor mange sigaretter røyker du vanligvis daglig?
 
Nei
 
Ja
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    27. Hvor gammel var du da du begynte å røyke?:_________ år 
 
 
    28. Hvor mange år til sammen har du røykt daglig?:_______ år 
 
        
    29. Dersom du røyker, har du da vurdert å slutte?  Ja  Nei 
 
 
    30. Hvis du har brukt andre former for nikotin siste året og fremdeles bruker det, kryss      
         av for hvilken type: 
         Ja           Nei 
Skrå/tyggetobakk/snus   bruker fremdeles 
  
Nikotintyggegummi   bruker fremdeles 
 
Nikotinplaster   bruker fremdeles 
 
Nikotininhalator   bruker fremdeles 
 
 
 
 
 Hvis nei, gå til pkt. 36 
 
 
     32. Hvilken type alkohol drikker du vanligvis? (Sett eventuelt flere kryss) 
 
Lettøl   Rusbrus  
 
Øl                     Hetvin (sherry, portvin, madeira) 
  
Rødvin          Brennevin (vodka, gin, akevitt, cognac, whisky, likør) 
  
Hvitvin    
 
 
     33. Hvor mange ganger i måneden drikker du vanligvis alkohol? 
         (Regn ikke med lettøl. Sett 0 hvis mindre enn 1 i måneden) 
 
        Antall:__________ 
 
  
 
 
 
 
31. Drikker du alkohol? 
Ja
 
Nei
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   34. Hvor ofte har du drukket alkohol det siste året? 
         (Regn ikke med lettøl og alkoholfritt øl) 
 
 4-7 ganger i uken 
 
 2-3 ganger i uken 
 
 ca. 1 gang i uken 
 
 2-3 ganger i måneden 
 
 ca. 1 gang i måneden 
 
 Noen få ganger siste år 
 
 Ikke siste året 
 
Enheter alkohol 
For å sammenligne ulike typer alkohol spør vi etter det vi kaller alkoholenheter 
(= 1,5 cl ren alkohol). En alkoholenhet tilsvarer: 
1 flaske rusbrus / cider 
1 glass (0.33 liter) øl 
1 vinglass (12 cl) rød eller hvitvin  
1 hetvinsglass (7,5 cl), sherry eller annen hetvin 
1 drammeglass (4 cl) brennevin eller likør 
 
 
   35. Hvor mange enheter drikker du vanligvis når du nyter alkohol? 
  
10 eller flere   
 
7-9   
 
5-6   
 
3-4   
 
1-2   
 
Færre enn 1   
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 36. Ca. hvor mange ganger i løpet av det siste året har du drukket så mye som     
           
       minst 5 glass og/eller drinker i løpet av et døgn? 
 
          Antall:__________ 
 
 
 
 
 
Takk for besvarelsen! 
 
 
Ønsker du å få tilsendt et brev med kort oppsummering av resultatene av 
undersøkelsene vi har foretatt? 
 
Ja, send kun til meg 
 
Ja, send til meg, samt kopi til fastlege 
 
Nei, ønsker ikke brev tilsendt 
 
Nei, men ønsker brev sendt til fastlege 
 
 
Hvis man oppdager noe som trenger videre oppfølging, ønskes opplysningene sendt til 
din fastlege? 
 
    Ja   Nei 
                                   
    
Navn og adresse på fastlegen: 
 
_____________________________________________________________________  
 
_____________________________________________________________________ 
    
Eventuelle kommentarer: 
_____________________________________________________________________ 
 
_____________________________________________________________________  
 
37. Bruker du noen andre rusmidler? 
Ja
 
Nei

